The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications

Jiemiao Hu, Jun Yan, Ganesh Rao, Khatri Latha, Willem W Overwijk, Amy B. Heimberger, Shulin Li*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

32 Scopus citations

Abstract

Fibrinogen-like protein 2 (Fgl2), a member of the fibrinogen family, can be expressed as a membrane-associated protein with coagulation activity or in a secreted form possessing unique immune suppressive functions. The biological importance of Fgl2 is evident within viral-induced fibrin depositing inflammatory diseases and malignancies and provides a compelling rationale for Fgl2 expression to not only be considered as a disease biomarker but also as a therapeutic target. This article will provide a comprehensive review of the currently known biological properties of Fgl2 and clarifies future scientific directives.

Original languageEnglish (US)
Pages (from-to)325-339
Number of pages15
JournalInternational Reviews of Immunology
Volume35
Issue number4
DOIs
StatePublished - Jul 3 2016
Externally publishedYes

Keywords

  • DC maturation
  • fibrin deposit
  • glioblastoma
  • immune suppression
  • inflammatory diseases
  • liver injury
  • membrane-bound procoagulant
  • secreted immune checkpoint regulator
  • Tregs

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications'. Together they form a unique fingerprint.

Cite this